scholarly article | Q13442814 |
P2093 | author name string | Borba EF | |
Bonfá E | |||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chloroquine | Q422438 |
P304 | page(s) | 780-785 | |
P577 | publication date | 2001-04-01 | |
P1433 | published in | The Journal of Rheumatology | Q7743623 |
P1476 | title | Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy | |
P478 | volume | 28 |
Q34389286 | A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role |
Q82662437 | Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches |
Q41939554 | Antimalarials. A treatment option for every lupus patient!? |
Q34938841 | Aortic Atherosclerosis in Systemic Lupus Erythematosus |
Q37319989 | Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings |
Q37425906 | Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors |
Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
Q26741266 | Current and emerging treatment options in the management of lupus |
Q34648851 | Current and novel therapeutics in the treatment of systemic lupus erythematosus |
Q35188363 | Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. |
Q36126483 | Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus |
Q96231744 | Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial |
Q45983994 | Excess weight and associated risk factors in patients with systemic lupus erythematosus. |
Q28548561 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease |
Q64227620 | Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis |
Q64946853 | Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients. |
Q45256816 | Lipoprotein profile in limited systemic sclerosis. |
Q39608521 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome |
Q38026787 | New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. |
Q35148630 | Novel Approaches to Therapy for SLE. |
Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
Q94672281 | The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? |
Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
Search more.